Dr. Singal on the FDA Approval of Cabozantinib in HCC

Video

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the FDA approval of cabozantinib (Cabometyx) for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar).

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the FDA approval of cabozantinib (Cabometyx) for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar).

Related Videos
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Debu Tripathy, MD
Changchun Deng, MD, PhD
Joaquim Bellmunt, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Ramez Kouzy, MD, MD Anderson
Bernard A. Fox, PhD
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus
Related Content
Jean-Yves Blay, MD, PhD, of Comprehensive Cancer Centre of Lyon

Additional 3 Years of Adjuvant Imatinib Maintenance Reduces Recurrence Risk in High-Risk GIST

May 9th 2024
Article
Gina Z. D’Amato, MD

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023
Podcast
US FDA

FDA Grants Orphan Drug Designation to 9MW2821 for Esophageal Cancer

May 8th 2024
Article
Nicholas Acuna, MPH

Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent

December 12th 2022
Podcast
Marjorie Green, MD

Frontline Pembrolizumab Plus Trastuzumab/Chemo Meets OS End Point in HER2+ Gastric/GEJ Cancer

May 1st 2024
Article
Kian-Huat Lim, MD, PhD

Patient Factors, Toxicities Key to Selecting NALIRIFOX or Other Chemo Options in Advanced Pancreatic Cancer

April 30th 2024
Article